Ausgabe 2/2010
Inhalt (17 Artikel)
Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors
Rebecca Liu, Duane A. Mitchell
Multimer technologies for detection and adoptive transfer of antigen-specific T cells
Rosaely Casalegno-Garduño, Anita Schmitt, Junxia Yao, Xinchao Wang, Xun Xu, Mathias Freund, Michael Schmitt
Loci controlling lymphocyte production of interferon γ after alloantigen stimulation in vitro and their co-localization with genes controlling lymphocyte infiltration of tumors and tumor susceptibility
Marie Lipoldová, Helena Havelková, Jana Badalová, Jarmila Vojtíšková, Lei Quan, Magdaléna Krulová, Yahya Sohrabi, Alphons P. Stassen, Peter Demant
Systemic dysregulation of CEACAM1 in melanoma patients
Gal Markel, Rona Ortenberg, Rachel Seidman, Sivan Sapoznik, Nira Koren-Morag, Michal J. Besser, Jair Bar, Ronnie Shapira, Adva Kubi, Gil Nardini, Ariel Tessone, Avraham J. Treves, Eyal Winkler, Arie Orenstein, Jacob Schachter
Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo)
Cecilie Totland, Geir Bredholt, Mette Haugen, Bjørn Ivar Haukanes, Christian A. Vedeler
Assessment of the pre-clinical immunogenicity of a new VEGF receptor Fc-fusion protein FP3 with ELISA and BIACORE
Hui Wang, Jing Shi, Qin Wang, Hong Li, Kun Cai, Xiaojun Hou, Tao Li, Qi Zhong, Dechao Yu
Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin
Wei Luo, Wang-Jun Liao, Li Ma, Yong-Ta Huang, Min Shi, Qian Wen, Xiao-Ning Wang
A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
Pina M. Cardarelli, Chetana Rao-Naik, Sharline Chen, Haichun Huang, Amie Pham, Maria-Cristina Moldovan-Loomis, Chin Pan, Ben Preston, David Passmore, Jie Liu, Michelle R. Kuhne, Alison Witte, Diann Blanset, David J. King
Tumors induce the formation of suppressor endothelial cells in vivo
Jennifer Konopa Mulligan, M. Rita I. Young
The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy
Xia Wu, Qin-Mei Feng, Ying Wang, Jun Shi, Hai-Liang Ge, Wen Di
A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer
Anda M. Vlad, Raluca A. Budiu, Diana E. Lenzner, Yun Wang, Julia A. Thaller, Kelly Colonello, Peggy A. Crowley-Nowick, Joseph L. Kelley, Fredric V. Price, Robert P. Edwards
Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
Marna G. Bouwhuis, Andreas Gast, Adina Figl, Alexander M. M. Eggermont, Kari Hemminki, Dirk Schadendorf, Rajiv Kumar
Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells
Bo Li, Zhang Lei, Brain D. Lichty, Dong Li, Gui-Mei Zhang, Zuo-Hua Feng, Yonghong Wan, Bo Huang
Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection
I-Hsuan Chen, Yuen-Liang Lai, Chien-Liang Wu, Yi-Fang Chang, Chen-Chung Chu, I-Fang Tsai, Fang-Ju Sun, Yen-Ta Lu
Impact of Cytomegalovirus infection on immune signatures in cancer patients
Evelyna Derhovanessian
Response to Dr Derhovanessian “Impact of cytomegalovirus infection on immune signatures in cancer patients”
Yen-Ta Lu, I-Hsuan Chen
Erratum to: Amyloid precursor-like protein 2 association with HLA class I molecules
Amit Tuli, Mahak Sharma, Xiaojian Wang, Laura C. Simone, Haley L. Capek, Steven Cate, William H. Hildebrand, Naava Naslavsky, Steve Caplan, Joyce C. Solheim